The prevalence of delirium in patients in Iran: a systematic review and meta-analysis

IF 0.6 Q4 CLINICAL NEUROLOGY

Future Neurology Pub Date : 2019-11-01 DOI:10.2217/fnl-2018-0044

E. Khalighi, A. Tarjoman, A. Abdi, M. Borji

{"title":"The prevalence of delirium in patients in Iran: a systematic review and meta-analysis","authors":"E. Khalighi, A. Tarjoman, A. Abdi, M. Borji","doi":"10.2217/fnl-2018-0044","DOIUrl":null,"url":null,"abstract":"Aim: The first systematic review and meta analysis investigating the prevalence of delirium in Iran and the importance of delirium in the health status of patients. Method: This study is a review article to determine the overall prevalence of delirium in patients admitted to the hospitals in Iran, with search time frame to 12 October 2000–12 October 2018. The study examined the prevalence of delirium in general wards and ICUs of Iran according to published article in domestic and foreign journals. The methodological quality of the papers was based on a tool used in previous studies. Data was analyzed using comprehensive meta-analysis (CMA) software. Findings: The findings showed the prevalence of delirium in hospitalized patients in Iran is 21.8% (CI: 17.5–27.5%). The prevalence of delirium in hospitalized patients in Iran based on the hospitalization in ICU is 24.7% (CI: 18.1–32.7%) and in the general ward is 17.5% (CI: 13.6–22.3%). Conclusion: Due to the relatively high prevalence of delirium in patients admitted to hospitals in Iran, prevention is necessary to reduce the incidence of delirium.","PeriodicalId":12606,"journal":{"name":"Future Neurology","volume":" ","pages":""},"PeriodicalIF":0.6000,"publicationDate":"2019-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/fnl-2018-0044","citationCount":"12","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Neurology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/fnl-2018-0044","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 12

Abstract

Aim: The first systematic review and meta analysis investigating the prevalence of delirium in Iran and the importance of delirium in the health status of patients. Method: This study is a review article to determine the overall prevalence of delirium in patients admitted to the hospitals in Iran, with search time frame to 12 October 2000–12 October 2018. The study examined the prevalence of delirium in general wards and ICUs of Iran according to published article in domestic and foreign journals. The methodological quality of the papers was based on a tool used in previous studies. Data was analyzed using comprehensive meta-analysis (CMA) software. Findings: The findings showed the prevalence of delirium in hospitalized patients in Iran is 21.8% (CI: 17.5–27.5%). The prevalence of delirium in hospitalized patients in Iran based on the hospitalization in ICU is 24.7% (CI: 18.1–32.7%) and in the general ward is 17.5% (CI: 13.6–22.3%). Conclusion: Due to the relatively high prevalence of delirium in patients admitted to hospitals in Iran, prevention is necessary to reduce the incidence of delirium.

查看原文本刊更多论文

伊朗患者谵妄患病率的系统综述和荟萃分析

目的：首次对伊朗谵妄的患病率以及谵妄对患者健康状况的重要性进行系统综述和荟萃分析。方法：本研究是一篇综述性文章，旨在确定伊朗医院收治患者的谵妄总体患病率，搜索时间范围为2000年10月12日至2018年10月31日。根据国内外期刊上发表的文章，该研究调查了伊朗普通病房和重症监护室的谵妄患病率。论文的方法论质量是基于以前研究中使用的工具。使用综合荟萃分析（CMA）软件对数据进行分析。研究结果：研究结果显示，伊朗住院患者的谵妄患病率为21.8%（CI:17.5-27.5%）。伊朗住院患者在ICU住院期间的谵妄发病率为24.7%（CI:18.1-32.7%），在普通病房为17.5%（CI:13.6-22.3%）在伊朗，预防是减少谵妄发生率的必要措施。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future Neurology CLINICAL NEUROLOGY-

CiteScore

2.10

自引率

0.00%

发文量

期刊介绍： The neurological landscape is changing rapidly. From the technological perspective, advanced molecular approaches and imaging modalities have greatly increased our understanding of neurological disease, with enhanced prospects for effective treatments in common but very serious disorders such as stroke, epilepsy, multiple sclerosis and Parkinson’s disease. Nevertheless, at the same time, the healthcare community is increasingly challenged by the rise in neurodegenerative diseases consequent upon demographic changes in developed countries.